Gateway Advisory LLC Invests $1.74 Million in AbbVie Inc. (ABBV) Stock

Gateway Advisory LLC acquired a new position in shares of AbbVie Inc. (NYSE:ABBV) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 24,036 shares of the company’s stock, valued at approximately $1,743,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Acropolis Investment Management LLC acquired a new stake in AbbVie during the second quarter worth about $106,000. Franklin Parlapiano Turner & Welch LLC acquired a new stake in AbbVie during the first quarter worth about $108,000. Atwood & Palmer Inc. raised its stake in AbbVie by 1,333.3% during the first quarter. Atwood & Palmer Inc. now owns 2,150 shares of the company’s stock worth $140,000 after acquiring an additional 2,000 shares during the period. Tradewinds Capital Management LLC raised its stake in AbbVie by 87.2% during the first quarter. Tradewinds Capital Management LLC now owns 2,269 shares of the company’s stock worth $148,000 after acquiring an additional 1,057 shares during the period. Finally, Exane Asset Management acquired a new stake in AbbVie during the second quarter worth about $181,000. Hedge funds and other institutional investors own 68.25% of the company’s stock.

In other AbbVie news, CEO Richard A. Gonzalez sold 65,861 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $71.00, for a total value of $4,676,131.00. Following the completion of the sale, the chief executive officer now owns 342,353 shares in the company, valued at approximately $24,307,063. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Richard A. Gonzalez sold 193,131 shares of the firm’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $71.00, for a total transaction of $13,712,301.00. Following the completion of the sale, the chairman now owns 469,623 shares of the company’s stock, valued at approximately $33,343,233. The disclosure for this sale can be found here. Insiders sold a total of 379,890 shares of company stock valued at $27,187,817 in the last 90 days. Corporate insiders own 0.23% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was published by Markets Daily and is the property of of Markets Daily. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.themarketsdaily.com/2017/10/18/gateway-advisory-llc-invests-1-74-million-in-abbvie-inc-abbv-stock.html.

Several equities research analysts recently weighed in on the stock. UBS AG reiterated a “neutral” rating on shares of AbbVie in a research note on Friday, October 13th. Barclays PLC increased their price objective on shares of AbbVie to $90.00 and gave the stock an “equal weight” rating in a research note on Friday, October 13th. Cowen and Company upgraded shares of AbbVie from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $91.17 to $105.00 in a research note on Wednesday, October 11th. Zacks Investment Research upgraded shares of AbbVie from a “hold” rating to a “buy” rating and set a $102.00 price objective on the stock in a research note on Tuesday. Finally, Jefferies Group LLC increased their price objective on shares of AbbVie from $107.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday. Seven investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $92.79.

AbbVie Inc. (NYSE ABBV) opened at 92.17 on Wednesday. AbbVie Inc. has a 12-month low of $55.06 and a 12-month high of $92.78. The company has a market capitalization of $146.93 billion, a PE ratio of 22.67 and a beta of 1.51. The stock has a 50 day moving average of $85.49 and a 200 day moving average of $72.96.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 28th. The company reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.02. The firm had revenue of $6.94 billion during the quarter, compared to analysts’ expectations of $6.93 billion. AbbVie had a net margin of 24.77% and a return on equity of 150.27%. The company’s quarterly revenue was up 7.6% compared to the same quarter last year. During the same quarter last year, the company posted $1.26 EPS. On average, equities research analysts predict that AbbVie Inc. will post $5.53 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th will be given a $0.64 dividend. This represents a $2.56 annualized dividend and a yield of 2.78%. The ex-dividend date of this dividend is Thursday, October 12th. AbbVie’s payout ratio is presently 62.90%.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply